Pharmaceutical application of combination of salvianolic acid A, salvianolic acid B and salvianolic acid C for resisting 2019-nCov virus and medicine

A 2019-ncov, salvianolic acid technology, applied in the field of antiviral drug preparation

Inactive Publication Date: 2021-05-18
XI AN JIAOTONG UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Salvianolic acid A, salvianolic acid B, and salvianolic acid C are the main active components of the traditional Chinese medicine Danshen, and there is no report on their anti-2019-nCoV virus effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of combination of salvianolic acid A, salvianolic acid B and salvianolic acid C for resisting 2019-nCov virus and medicine
  • Pharmaceutical application of combination of salvianolic acid A, salvianolic acid B and salvianolic acid C for resisting 2019-nCov virus and medicine
  • Pharmaceutical application of combination of salvianolic acid A, salvianolic acid B and salvianolic acid C for resisting 2019-nCov virus and medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1, SPR method detects the binding ability of salvianolic acid A, salvianolic acid B and salvianolic acid C and ACE2 protein and S protein

[0026] Experimental materials: ACE2 protein (purchased from Beijing Yiqiao), salvianolic acid A (purchased from Baoji Chenguang), salvianolic acid B (purchased from Shanghai Anpu) and salvianolic acid C (purchased from Baoji Chenguang), SPR, COOH Chips and corresponding activation reagents (purchased from Nicoya, Canada).

[0027] Preparation method: install a carboxyl chip in the Open SPR instrument, and pump the running buffer at the maximum flow rate (150 μL / min) to make it full of the detection cell. After reaching the signal baseline, inject 80% isopropanol to degas and clean the chip surface with 10 mM HCl. After reaching the signal baseline again, adjust the flow rate to 20 μL / min. Immediately mix an equal amount of coupling reagent (EDC / NHS) and inject it into the injection valve, activate the chip for 5 minutes...

Embodiment 2

[0030] Example 2. Salvianolic acid A, salvianolic acid B and salvianolic acid C inhibit 2019-nCov pseudovirus from infecting cells with high expression of ACE2.

[0031] ACE2 high-expressing cells were seeded in 96-well plates, and each well was supplemented with medium to 50 μL. 37°C, 5% CO 2 Incubate in the incubator for 2 hours to adhere to the wall. Add 20 μM salvianolic acid A, salvianolic acid B or salvianolic acid C prepared in culture medium respectively, add 5uL 2019-CoV-2 Spike pseudovirus to each well for 4 hours, make up to 100 μL culture volume, continue infection for 6-8 hours, replace Make 200 μL of new complete medium and continue culturing at 37°C for 48h. The Luciferase Assay System kit detects the luminescence value of Luciferase.

[0032] see image 3 , after administration, the luminous intensity of Luciferase decreased compared with the control group. Chloroquine (20 μM) was used as an antiviral positive control. From image 3 It can be seen from t...

Embodiment 3

[0033] Example 3 Combined administration of salvianolic acid A, salvianolic acid B and salvianolic acid C inhibits 2019-nCov pseudovirus from infecting cells with high expression of ACE2.

[0034] ACE2 high-expressing cells were seeded in 96-well plates, and each well was supplemented with medium to 50 μL. 37°C, 5% CO 2 Incubate in the incubator for 2 hours to adhere to the wall. 10 μM salvianolic acid B or 2.5 μM salvianolic acid A, 5 μM salvianolic acid B and 2.5 μM salvianolic acid C were administered alone, and incubated at 37°C for 2 hours. Add 5uL 2019-CoV-2 Spike pseudovirus to each well to infect for 4 hours, make up to 100 μL culture volume, continue infection for 6-8 hours, replace with 200 μL new complete medium, and continue to culture at 37°C for 48 hours. The Luciferase AssaySystem kit detects the luminescence value of Luciferase.

[0035] see Figure 4 , after co-administration, the luminous intensity of Luciferase decreased compared with the control group. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical application of a combination of salvianolic acid A, salvianolic acid B and salvianolic acid C for resisting 2019-nCoV virus and a medicine, and belongs to the technical field of preparation of antiviral medicines. The inhibition effect of the combined medicine on the 2019-nCoV virus is evaluated through the combination effect of the medicine and ACE2 protein and the pseudovirus infection capacity, and it is determined that the medicine for resisting the 2019-nCoV virus can be prepared when the salvianolic acid A, the salvianolic acid B and the salvianolic acid C are combined for use. The combined administration of the salvianolic acid A, the salvianolic acid B and the salvianolic acid C has the capability of reducing 2019-nCoV pseudovirus infection more effectively than the single administration, so that the salvianolic acid A, the salvianolic acid B and the salvianolic acid C have an antiviral effect. In addition, the salvianolic acid A, the salvianolic acid B and the salvianolic acid C also have various pharmacological activities of protecting myocardium, protecting heart, resisting fibrosis, resisting tumors and the like, and are small in side effect and low in toxicity, so that the salvianolic acid A, the salvianolic acid B and the salvianolic acid C have important significance as the medicine for resisting the 2019-nCoV virus.

Description

technical field [0001] The invention belongs to the technical field of antiviral drug preparation, and relates to the pharmaceutical application and drug of salvianolic acid A, salvianolic acid B and salvianolic acid C combined with anti-2019-nCov virus. Background technique [0002] The clinical classification of the disease caused by the new coronavirus (2019-nCoV) is mild, common, severe and critical. The main manifestations are fever, dry cough, fatigue, etc., and a small number of patients are accompanied by nasal congestion, runny nose, diarrhea, etc. Gastrointestinal symptoms. Severe cases often develop dyspnea after one week, and severe cases rapidly progress to acute respiratory distress syndrome, septic shock, difficult-to-correct metabolic acidosis, coagulation dysfunction, and multiple organ failure. [0003] 2019-nCoV is a positive single-stranded RNA virus whose envelope has a prominent corona protein (S protein), similar to SARS coronavirus (SARS-CoV), throug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61K31/216A61P31/14A61P11/00
CPCA61K31/216A61K31/343A61P31/14A61P11/00
Inventor 贺浪冲王楠卢闻展颖转胡时灵王珏
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap